JP2006526031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006526031A5 JP2006526031A5 JP2006519178A JP2006519178A JP2006526031A5 JP 2006526031 A5 JP2006526031 A5 JP 2006526031A5 JP 2006519178 A JP2006519178 A JP 2006519178A JP 2006519178 A JP2006519178 A JP 2006519178A JP 2006526031 A5 JP2006526031 A5 JP 2006526031A5
- Authority
- JP
- Japan
- Prior art keywords
- represented
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003148073 | 2003-05-26 | ||
| PCT/JP2004/007562 WO2004103369A1 (en) | 2003-05-26 | 2004-05-26 | Pharmaceutical composition containing histone deacetylase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006526031A JP2006526031A (ja) | 2006-11-16 |
| JP2006526031A5 true JP2006526031A5 (enExample) | 2006-12-28 |
Family
ID=33475383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006519178A Pending JP2006526031A (ja) | 2003-05-26 | 2004-05-26 | ヒストンデアセチラーゼ阻害物質を含む医薬組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20070098816A1 (enExample) |
| EP (1) | EP1626719A1 (enExample) |
| JP (1) | JP2006526031A (enExample) |
| KR (1) | KR100938712B1 (enExample) |
| CN (2) | CN101322707A (enExample) |
| AR (1) | AR045318A1 (enExample) |
| AU (1) | AU2004241873C1 (enExample) |
| BR (1) | BRPI0410959A (enExample) |
| CA (4) | CA2634766A1 (enExample) |
| CL (1) | CL2004001278A1 (enExample) |
| CO (1) | CO5660262A2 (enExample) |
| CR (1) | CR8163A (enExample) |
| CU (1) | CU23490B7 (enExample) |
| EC (1) | ECSP056253A (enExample) |
| IL (1) | IL171941A0 (enExample) |
| ME (1) | MEP32308A (enExample) |
| MX (1) | MXPA05012345A (enExample) |
| NO (1) | NO20055417L (enExample) |
| NZ (1) | NZ543591A (enExample) |
| PE (1) | PE20050206A1 (enExample) |
| RS (1) | RS20050884A (enExample) |
| RU (1) | RU2322971C2 (enExample) |
| TW (1) | TW200505424A (enExample) |
| UA (1) | UA81499C2 (enExample) |
| UY (1) | UY28330A1 (enExample) |
| WO (1) | WO2004103369A1 (enExample) |
| ZA (1) | ZA200509515B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| KR20050122210A (ko) | 2003-03-17 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| CA2540108A1 (en) * | 2003-09-25 | 2005-04-07 | Astellas Pharma Inc. | Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
| EP1712552A1 (en) * | 2005-04-11 | 2006-10-18 | INDENA S.p.A. | Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel |
| US7446126B2 (en) * | 2004-10-08 | 2008-11-04 | Indena S.P.A. | Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel |
| JP2008524246A (ja) | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| KR20080003334A (ko) * | 2005-03-11 | 2008-01-07 | 더 리젠트스 오브 더 유니버시티 오브 콜로라도 | 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제 |
| US8999289B2 (en) | 2005-03-22 | 2015-04-07 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
| WO2006122319A2 (en) | 2005-05-11 | 2006-11-16 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| ZA200800901B (en) | 2005-07-14 | 2010-05-26 | Takeda San Diego Inc | Histone deacetylase inhibitors |
| US8222423B2 (en) | 2006-02-14 | 2012-07-17 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
| JP5409015B2 (ja) | 2006-02-14 | 2014-02-05 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | ヒストンデアセチラーゼ阻害剤 |
| AU2007248656B2 (en) | 2006-05-03 | 2013-04-04 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase and tubulin deacetylase inhibitors |
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| PT2099442E (pt) | 2006-12-26 | 2015-02-10 | Pharmacyclics Inc | Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação |
| WO2009067453A1 (en) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
| US8293513B2 (en) * | 2007-12-14 | 2012-10-23 | Georgetown University | Histone deacetylase inhibitors |
| US8440716B2 (en) | 2008-07-23 | 2013-05-14 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
| SI2350005T1 (sl) * | 2008-08-29 | 2012-03-30 | Bayer Pharma AG | Polimorf B N aminofenil N piridin il metoksikarbonilaminometil benzamida MS |
| GB2462893B (en) * | 2008-08-29 | 2010-10-13 | Bayer Schering Pharma Ag | N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B |
| BRPI0924084B1 (pt) | 2008-12-19 | 2021-12-21 | Vertex Pharmaceuticals Incorporated | Derivados de pirazina e composição farmacêutica que os compreende |
| EP2395972A4 (en) * | 2009-02-11 | 2014-02-12 | Liangping Yu | PARTICULATE COMPOSITION AND METHOD FOR PRODUCING THE SAME |
| EP2424516A4 (en) * | 2009-05-01 | 2014-04-02 | Oncozyme Pharma Inc | PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER |
| KR20120031170A (ko) * | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| US8716344B2 (en) | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
| JP2013503174A (ja) * | 2009-08-25 | 2013-01-31 | アブラクシス バイオサイエンス， エルエルシー | タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法 |
| AU2011253025A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| NZ621221A (en) | 2011-09-13 | 2016-07-29 | Pharmacyclics Llc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
| IN2014CN02501A (enExample) * | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
| SG10201606774UA (en) | 2011-09-30 | 2016-10-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
| WO2013085902A1 (en) * | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| US20140044802A1 (en) | 2012-04-05 | 2014-02-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| US9738637B2 (en) | 2013-03-12 | 2017-08-22 | Celgene Quantical Research, Inc. | Histone demethylase inhibitors |
| WO2014141129A2 (en) * | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
| EA201592012A8 (ru) * | 2014-02-21 | 2018-10-31 | Общество С Ограниченной Ответственностью "Биолаб 612" | Применение флагеллина для улучшенной химиотерапии |
| EA201790604A1 (ru) | 2014-09-17 | 2017-09-29 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы гистондеметилазы |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US11596612B1 (en) | 2022-03-08 | 2023-03-07 | PTC Innovations, LLC | Topical anesthetics |
| WO2025041160A1 (en) * | 2023-08-19 | 2025-02-27 | Birla Institute Of Technology And Science (Bits), Pilani | Bifunctional conjugate molecules for cancer treatment and process of making the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| JP3354090B2 (ja) * | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
| US6794392B1 (en) * | 1996-09-30 | 2004-09-21 | Schering Aktiengesellschaft | Cell differentiation inducer |
| US5753637A (en) * | 1996-10-09 | 1998-05-19 | Ideal Ideas, Inc. | Method of treating acne conditions |
| YU22401A (sh) * | 1998-09-25 | 2004-03-12 | Warner-Lambert Company | Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom |
| EP1177796B1 (en) * | 1999-04-27 | 2011-04-27 | Mitsubishi Tanabe Pharma Corporation | Medicament for prevention or therapeutic treatment of liver disease |
| NZ518668A (en) * | 1999-11-10 | 2004-04-30 | Warner Lambert Co | Combination chemotherapy comprising acetyldinaline and paclitaxal and/or carboplatin |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| CZ20022216A3 (cs) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Kombinační chemoterapie |
| JP2003137866A (ja) * | 2001-11-01 | 2003-05-14 | Sankyo Co Ltd | フェニレンジアミン誘導体 |
-
2004
- 2004-05-25 PE PE2004000533A patent/PE20050206A1/es not_active Application Discontinuation
- 2004-05-26 CL CL200401278A patent/CL2004001278A1/es unknown
- 2004-05-26 CA CA002634766A patent/CA2634766A1/en not_active Abandoned
- 2004-05-26 CA CA002634709A patent/CA2634709A1/en not_active Abandoned
- 2004-05-26 UA UAA200512454A patent/UA81499C2/xx unknown
- 2004-05-26 MX MXPA05012345A patent/MXPA05012345A/es active IP Right Grant
- 2004-05-26 AR ARP040101807A patent/AR045318A1/es not_active Application Discontinuation
- 2004-05-26 CA CA002634765A patent/CA2634765A1/en not_active Abandoned
- 2004-05-26 ME MEP-323/08A patent/MEP32308A/xx unknown
- 2004-05-26 NZ NZ543591A patent/NZ543591A/en unknown
- 2004-05-26 CA CA002527191A patent/CA2527191A1/en not_active Abandoned
- 2004-05-26 JP JP2006519178A patent/JP2006526031A/ja active Pending
- 2004-05-26 CN CNA2008101007303A patent/CN101322707A/zh active Pending
- 2004-05-26 RS YUP-2005/0884A patent/RS20050884A/sr unknown
- 2004-05-26 CN CNA2004800146332A patent/CN1794991A/zh active Pending
- 2004-05-26 EP EP04734923A patent/EP1626719A1/en not_active Withdrawn
- 2004-05-26 US US10/558,208 patent/US20070098816A1/en not_active Abandoned
- 2004-05-26 WO PCT/JP2004/007562 patent/WO2004103369A1/en not_active Ceased
- 2004-05-26 BR BRPI0410959-7A patent/BRPI0410959A/pt not_active IP Right Cessation
- 2004-05-26 UY UY28330A patent/UY28330A1/es not_active Application Discontinuation
- 2004-05-26 KR KR1020057022615A patent/KR100938712B1/ko not_active Expired - Fee Related
- 2004-05-26 RU RU2005140570/15A patent/RU2322971C2/ru active IP Right Revival
- 2004-05-26 AU AU2004241873A patent/AU2004241873C1/en not_active Ceased
- 2004-05-26 TW TW093114934A patent/TW200505424A/zh unknown
-
2005
- 2005-11-14 IL IL171941A patent/IL171941A0/en unknown
- 2005-11-16 NO NO20055417A patent/NO20055417L/no not_active Application Discontinuation
- 2005-11-24 ZA ZA200509515A patent/ZA200509515B/en unknown
- 2005-11-25 CU CU20050237A patent/CU23490B7/es not_active IP Right Cessation
- 2005-12-22 CO CO05129159A patent/CO5660262A2/es unknown
- 2005-12-26 EC EC2005006253A patent/ECSP056253A/es unknown
-
2006
- 2006-01-02 CR CR8163A patent/CR8163A/es not_active Application Discontinuation